This issue of Prescriber features topics that are currently very active areas of drug research, as well as having high media profiles – the influence of the human gut microbiome on drug metabolism and the medicinal use of cannabis-derived products
Articles: 29.08 August 2018
Optimising COPD management, tackling hypoglycaemia in diabetes and NHS England’s Medicines Value Programme were among the topics discussed at Clinical Pharmacy Congress 2018 held in London in April. This article provides an overview of some of the presentations
Current guidelines recommend reducing LDL cholesterol by specified amounts; however, a new treatment ‘lower is better’ paradigm advocates more dramatic LDL cholesterol reduction beyond current targets to maximise global cardiovascular risk benefits. This article examines the benefits and drawbacks of this approach.
It is now 15 years since the Department of Health first announced its plans for the establishment of consultant pharmacist posts in the NHS. This article examines how the role is developing and how it differs from that of an advanced clinical pharmacist practitioner
The human gut microbiome has a crucial role in both health and disease, including drug metabolism. Recent research indicates that boosting the microbiome (for example, by using pro- or prebiotics) is a promising therapeutic strategy that could enhance the efficacy and reduce the toxicity of many medicines.
In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management of migraine (SIGN 155). This article discusses the main recommendations of the guidance and how it compares with other UK headache guidelines, including
The relationship between polypharmacy and frailty was the subject of the 2018 Annual Scientific Meeting of PRIMM (Prescribing and Research in Medicines Management), held in London in January. Professor Janet Krska reports on some of the advice given at the meeting, including identifying frailty and …